Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

2009 Biopharma Deals Of The Year: Roche/Genentech, Movetis' IPO, Elan/J&J

  • Analysis

Executive Summary

Which pharmaceutical and biotech deal-making and financing developments of the past year are the most surprising, creative or precedent-setting

You may also be interested in...



Financings Of The Fortnight: Movetis Files First European Biopharma IPO Since Early 2008

Notable biotech financings in November also include ThromboGenics, NicOx: 4SC AG, and Fate Therapeutics.

A Solution For Elan: It Strikes A Deal With J&J On Key Alzheimer's Assets

J&J gets to build its fledgling Alzheimer's program, while Elan gets cash to strengthen its balance sheet, plus a new minority shareholder and strong global partner.

Roche Wins Genentech After Months-Long Battle

The hard task of integration—and the battle to retain Genentech employees—begins, while the DNA ticker symbol is up for grabs.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Next UK Drug Pricing Scheme Needs ‘Single-Digit Fixed Rebates’

Pharmacies Likely To Cease Prescribing COVID-19 Therapeutics With End Of Public Health Emergency

The IRA And US FDA: How Will Agency View Any Drug Development Changes?

Accelerated Approval: US FDA Should Explain Why An Ongoing Trial Is Not Required

See All
UsernamePublicRestriction

Register

PS051810

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By